Clinical trial NCT01113970: Study of a Novel Indibulin Dosing Schedule for the Treatment of Metastatic Breast Cancer
Official title: Phase I/II Study of a Novel Indibulin Dosing Schedule for the Treatment of Metastatic Breast Cancer
Study type: INTERVENTIONAL
Overall status: UNKNOWN
Phase: PHASE1
PHASE2
Conditions: Metastatic Breast Cancer
Keywords: breast cancer
Indibulin
unresectable, locally advanced breast cancer
Lead sponsor: Alaunos Therapeutics
Sponsor class: INDUSTRY
Collaborators: name: Memorial Sloan Kettering Cancer Center
First posted: 2010-04-30
Enrollment: 60
Sex: ALL
Minimum age (years): 18
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Allocation: NA
Intervention model: SINGLE_GROUP
Primary purpose: TREATMENT

Brief summary: This study is a Phase I/II trial of a novel Indibulin dosing schedule for the treatment of metastatic breast cancer. Eligible patients will have measurable or non-measurable, metastatic or unresectable, locally advanced breast cancer and may have received any number of prior therapies for their disease.

It is expected that the Phase I portion will enroll up to 20 patients and the Phase II portion will enroll up to 45 patients.


Eligibility criteria: Inclusion Criteria:

* Histologic or cytologic confirmation of invasive carcinoma of the breast.
* Clinical evidence of metastatic disease or locally advanced disease not amenable to curative therapy.
* Measurable or non-measurable lesions according to the RECIST Version 1.1 2009.
* Any number of prior endocrine, biologic or chemotherapy regimens is permitted. All previous chemotherapy and biologic therapy must have been discontinued at least 3 weeks prior to beginning study drug. Endocrine therapy may not be used concurrently with protocol treatment. All acute toxic effects (excluding alopecia or neuropathy) of any prior therapy must have resolved to NCI CTC (version 4.0) Grade ≤ 1 or to baseline
* Prior radiation therapy is permitted.
* ECOG performance status of 0, 1 or 2.
* Age ≥ 18 years
* Life expectancy ≥ 12 weeks
* Patients with HER2-positive (IHC 3+ or FISH-amplified) breast cancer must have received trastuzumab or have a contradiction to receiving HER2- targeted therapy (such as abnormal left ventricular ejection fraction)as determined by the treating physician.
* Adequate bone marrow, liver and renal function as assessed by the following laboratory requirements:

  * Creatinine ≤ 1.5x upper limit of normal (ULN)
  * Total bilirubin ≤ 1.5x ULN
  * ALT or AST ≤ 2.5x ULN
  * ANC ≥ 1.5 x10(9)/L
  * Platelets ≥ 100 x10(9)/L
  * Hemoglobin ≥ 9g/dL
* Subjects of childbearing potential must agree to use a barrier method of contraception throughout the study and for 3 months after study drug administration.

Exclusion Criteria:

* Pregnant or nursing women may not participate.
* Serious, uncontrolled, concurrent infection.
* Patients with symptomatic CNS metastases that remain untreated by radiation therapy are excluded from this trial. The presence of asymptomatic, previously irradiated, stable brain metastases for at least 3 months are not grounds for trial exclusion.
* Presence of uncontrolled gastrointestinal malabsorption syndrome.
* Any chemotherapy, radiotherapy or breast cancer directed biologic therapy during the study or within 3 weeks of study start. Mitomycin C or nitrosureas should not be given within 6 weeks of study entry. No washout period is required for hormonal therapies.
* Concurrent radiation therapy is not permitted during treatment on protocol.
* History of an invasive second primary malignancy diagnosed within the previous 3 years, except for Stage I endometrial or cervical carcinoma or prostate carcinoma treated surgically, and non-melanoma skin cancer.
* Any medical, psychological or social condition that may interfere with the subject's ability to safely participate in the study.
* Unwillingness to give written informed consent or unwillingness to participate or inability to comply with the protocol for the duration of the study. Willingness and ability to comply with scheduled visits, treatment plan, laboratory tests and other study procedures are necessary for participation in this clinical trial.

Primary outcomes:
measure: Phase I- Maximum Tolerated Dose
timeFrame: Throughout Cycle 1 (28 days)
measure: Phase II- Progression Free Survival
timeFrame: 4 months
Secondary outcomes:
measure: Phase I- Number of participants with Adverse Events as a measure of safety and tolerability
timeFrame: Duration of study, approximately one year
measure: Phase I- Toxicity
timeFrame: Cycle 1 (28 days), and duration of study (approximately one year)
measure: Phase I- Pharmacokinetics of indibulin in study subject plasma assessed in Cycle 1 Day 1 and Cycle 1 Day 5 per schedule below in Description section.
timeFrame: During Cycle 1 (28 days)
measure: Phase II- Overall Response Rate
timeFrame: At the end of Cycles 4 and 6 (approximately 4 months and 6 months respectively)
measure: Phase II- Rate of Stable Disease
timeFrame: Phase II- greater than 6 months
measure: Phase II- Number of patients with Adverse Events as a measure of safety and tolerability
timeFrame: Throughout study, approximately one year
Other outcomes:
Locations:
city: New York
country: United States
facility: Memorial Sloan-Kettering Cancer Center
state: New York
city: Memphis
country: United States
facility: The West Clinic
state: Tennessee
city: Spokane
country: United States
facility: Evergreen Hematology Oncology
state: Washington
city: Vancouver
country: United States
facility: Northwest Cancer Specialists
state: Washington
Study officials:
affiliation: ZIOPHARM, Oncology, Inc.
name: Jonathan J. Lewis, MD, PhD
role: STUDY_DIRECTOR
References:
citation: Kapoor S, Srivastava S, Panda D. Indibulin dampens microtubule dynamics and produces synergistic antiproliferative effect with vinblastine in MCF-7 cells: Implications in cancer chemotherapy. Sci Rep. 2018 Aug 17;8(1):12363. doi: 10.1038/s41598-018-30376-y.